Sorriso Pharmaceuticals Launches with $31 Million to Develop Novel Class of Orally Delivered Cytokine Antibodies to Treat Inflammatory Conditions
/PRNewswire/ -- Sorriso Pharmaceuticals, a company focused on transforming anti-inflammatory antibody therapy, today announced the company has closed on a $31...